Intelligence · Clinical Development
Pipeline search results
Programs matching “alirocumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 27 pipeline programs matching "alirocumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Alirocumab
The First People's Hospital of Lianyungang
Intracranial Atherosclerosis
1 trial -
Alirocumab
Regeneron UK Limited
Homozygous Familial Hypercholesterolemia
1 trial -
Alirocumab
Sanofi Pasteur
Atherosclerotic Cardiovascular Disease
1 trial -
Alirocumab
Sanofi Pasteur
Hypercholesterolemia
1 trial -
Alirocumab
Regeneron UK Limited
Atherosclerotic Cardiovascular Disease
1 trial -
Alirocumab
Regeneron UK Limited
Coronary Vessel
1 trial -
Alirocumab
Regeneron UK Limited
Hypercholesterolaemia
2 trials -
Alirocumab
Regeneron UK Limited
Hypercholesterolemia
18 trials -
Alirocumab
Regeneron UK Limited
Type2 Diabetes
1 trial -
Alirocumab 150 MG/ML [Praluent]
Regeneron UK Limited
Hemodialysis
1 trial -
Alirocumab SAR236553
Regeneron UK Limited
Hypercholesterolaemia
1 trial -
Placebo (for alirocumab)
Regeneron UK Limited
Hypercholesterolemia
5 trials -
alirocumab SAR236553 (REGN727)
Regeneron UK Limited
Hypercholesterolaemia
2 trials -
alirocumab SAR236553 (REGN727)
Regeneron UK Limited
Hypercholesterolemia
8 trials -
Alirocumab
Regeneron UK Limited
Non Small Cell Lung Cancer
1 trial -
Alirocumab
Regeneron UK Limited
Nephrotic Syndrome
1 trial -
Alirocumab and Cemiplimab
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Alirocumab
Regeneron UK Limited
Stroke
1 trial -
Alirocumab
Regeneron UK Limited
Sepsis
1 trial -
Alirocumab (Solution)
Regeneron UK Limited
Hypercholesterolemia
1 trial -
Alirocumab
Regeneron UK Limited
Myocardial Infarction
2 trials -
Alirocumab
Regeneron UK Limited
Dyslipidemia
1 trial -
Alirocumab
Regeneron UK Limited
Atherosclerosis
1 trial -
Alirocumab 150 MG/ML subcutaneous injection
Regeneron UK Limited
Saphenous Vein Graft Atherosclerosis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.